Lifeward (NASDAQ:LFWD – Get Free Report) had its target price lowered by investment analysts at HC Wainwright from $10.00 to $8.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 97.04% from the stock’s previous close.
LFWD has been the topic of a number of other reports. Zacks Research upgraded Lifeward from a “strong sell” rating to a “hold” rating in a research note on Monday, July 27th. Weiss Ratings lowered Lifeward from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, Citigroup reiterated a “buy” rating on shares of Lifeward in a research report on Friday, August 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.
Read Our Latest Stock Report on Lifeward
Lifeward Price Performance
Shares of NASDAQ:LFWD opened at $4.06 on Monday. The company has a quick ratio of 1.77, a current ratio of 2.33 and a debt-to-equity ratio of 0.70. The company has a market cap of $11.49 million, a P/E ratio of -0.26 and a beta of 0.55. Lifeward has a 52 week low of $3.81 and a 52 week high of $9.61. The company has a 50-day moving average price of $6.35 and a 200 day moving average price of $6.85.
Lifeward (NASDAQ:LFWD – Get Free Report) last released its earnings results on Saturday, August 15th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.07). The business had revenue of $6.62 million for the quarter, compared to analyst estimates of $6.53 million. Lifeward had a negative return on equity of 281.70% and a negative net margin of 155.37%. Research analysts predict that Lifeward will post -0.44 earnings per share for the current year.
Lifeward Company Profile
Lifeward Ltd. develops and markets medical devices for mobility, rehabilitation and physical therapy. Its products include wearable robotic exoskeletons designed to help people with mobility impairments stand and walk, as well as systems used in rehabilitation settings. The company’s offerings include the ReWalk exoskeleton for people with spinal cord injuries and the ReStore exo-suit for gait training after stroke. Lifeward also sells AlterG anti-gravity treadmills, which use differential air pressure to reduce the user’s effective body weight during walking or running exercises.
See Also
- Five stocks we like better than Lifeward
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.
